AZN.UK

12,434

+0.19%↑

GSK

1,648.5

-1.26%↓

HLN.UK

329.9

-1.17%↓

STJ

1,285.5

+0.82%↑

AZN.UK

12,434

+0.19%↑

GSK

1,648.5

-1.26%↓

HLN.UK

329.9

-1.17%↓

STJ

1,285.5

+0.82%↑

AZN.UK

12,434

+0.19%↑

GSK

1,648.5

-1.26%↓

HLN.UK

329.9

-1.17%↓

STJ

1,285.5

+0.82%↑

AZN.UK

12,434

+0.19%↑

GSK

1,648.5

-1.26%↓

HLN.UK

329.9

-1.17%↓

STJ

1,285.5

+0.82%↑

AZN.UK

12,434

+0.19%↑

GSK

1,648.5

-1.26%↓

HLN.UK

329.9

-1.17%↓

STJ

1,285.5

+0.82%↑

Search

Hikma Pharmaceuticals PLC

Abierto

SectorSanidad

1,825 1.61

Resumen

Variación precio

24h

Actual

Mínimo

1776

Máximo

1826

Métricas clave

By Trading Economics

Ingresos

133M

Ventas

100M

1.7B

P/B

Media del Sector

13.384

35.739

BPA

1.07

Rentabilidad por dividendo

5.06

Margen de beneficios

8.537

Empleados

9,500

EBITDA

-29M

259M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+37.72% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

5.06%

3.08%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.4B

3.7B

Apertura anterior

1823.39

Cierre anterior

1825

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

120 / 371 Clasificación en Healthcare

Hikma Pharmaceuticals PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

8 abr 2025, 08:20 UTC

Charlas de Mercado

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

Comparación entre iguales

Cambio de precio

Hikma Pharmaceuticals PLC previsión

Precio Objetivo

By TipRanks

37.72% repunte

Estimación a 12 Meses

Media 2,472 GBX  37.72%

Máximo 2,850 GBX

Mínimo 1,982 GBX

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hikma Pharmaceuticals PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

120 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
help-icon Live chat